Prulifloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Prulifloxacin
Accession Number
DB11892
Type
Small Molecule
Groups
Investigational
Description

Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
J42298IESW
CAS number
123447-62-1
Weight
Average: 461.46
Monoisotopic: 461.105684713
Chemical Formula
C21H20FN3O6S
InChI Key
PWNMXPDKBYZCOO-UHFFFAOYSA-N
InChI
InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
IUPAC Name
6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
SMILES
CC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N1CCN(CC2=C(C)OC(=O)O2)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Prulifloxacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Prulifloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Prulifloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Prulifloxacin.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Prulifloxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Prulifloxacin.Approved, Experimental, Investigational
AcenocoumarolPrulifloxacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Prulifloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Prulifloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Prulifloxacin.Approved
AlbiglutidePrulifloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Prulifloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Prulifloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Prulifloxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Prulifloxacin.Experimental
AlogliptinPrulifloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Prulifloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Prulifloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Prulifloxacin.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Amiodarone.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Prulifloxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Prulifloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Prulifloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Prulifloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
ApocyninApocynin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Prulifloxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Prulifloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Prulifloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Prulifloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Prulifloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Prulifloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Prulifloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Prulifloxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Benzatropine.Approved
BenzydamineBenzydamine may increase the neuroexcitatory activities of Prulifloxacin.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Prulifloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Prulifloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Prulifloxacin.Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Prulifloxacin.Approved
BromocriptinePrulifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Brompheniramine.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Prulifloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Prulifloxacin.Approved, Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prulifloxacin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Prulifloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinPrulifloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Prulifloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Prulifloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Cetirizine.Approved
ChloroquineChloroquine may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Chlorphenamine.Approved
ChlorpropamidePrulifloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Prulifloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Prulifloxacin.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Ciprofloxacin.Approved, Investigational
ClemastineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Prulifloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Prulifloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Prulifloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Prulifloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Prulifloxacin.Approved
ClorindionePrulifloxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Prulifloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Prulifloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Prulifloxacin.Approved, Investigational
CurcuminCurcumin may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Prulifloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Prulifloxacin.Experimental
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Prulifloxacin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Prulifloxacin.Approved, Investigational
DelamanidPrulifloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Prulifloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Prulifloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Prulifloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Prulifloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Prulifloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Prulifloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Prulifloxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Dexbrompheniramine.Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved
DicoumarolPrulifloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Prulifloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Prulifloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Prulifloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Prulifloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Prulifloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Prulifloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Prulifloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Prulifloxacin.Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Dimenhydrinate.Approved
DiphenadionePrulifloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Prulifloxacin.Approved, Investigational
DisopyramidePrulifloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prulifloxacin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Doxylamine.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Prulifloxacin.Withdrawn
DulaglutidePrulifloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Prulifloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Prulifloxacin.Investigational
EmpagliflozinPrulifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Prulifloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Prulifloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Prulifloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Prulifloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Prulifloxacin.Approved
EthenzamideEthenzamide may increase the neuroexcitatory activities of Prulifloxacin.Experimental
Ethyl biscoumacetatePrulifloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
ExenatidePrulifloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Prulifloxacin.Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Prulifloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Prulifloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Prulifloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Prulifloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Prulifloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric pyrophosphateThe serum concentration of Prulifloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Prulifloxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Prulifloxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Prulifloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Prulifloxacin.Approved, Investigational
FluindionePrulifloxacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Prulifloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Prulifloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Prulifloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Prulifloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Prulifloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Prulifloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Prulifloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Prulifloxacin.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Fluoxetine.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Prulifloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Prulifloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Prulifloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Prulifloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Prulifloxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Prulifloxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Prulifloxacin.Approved, Investigational, Withdrawn
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Prulifloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Prulifloxacin.Experimental
GliclazidePrulifloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Prulifloxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Prulifloxacin.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Prulifloxacin.Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Goserelin.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Prulifloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Prulifloxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Prulifloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Prulifloxacin.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Prulifloxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Prulifloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Prulifloxacin.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prulifloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Prulifloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Prulifloxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Prulifloxacin.Withdrawn
Insulin AspartPrulifloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPrulifloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be increased when used in combination with Prulifloxacin.Approved
Insulin GlulisinePrulifloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be increased when used in combination with Prulifloxacin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be increased when used in combination with Prulifloxacin.Approved
IronThe serum concentration of Prulifloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Prulifloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Prulifloxacin can be decreased when it is combined with Iron saccharate.Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Prulifloxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Prulifloxacin.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Prulifloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Prulifloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Prulifloxacin.Experimental
Lanthanum carbonateThe serum concentration of Prulifloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Leuprolide.Approved, Investigational
LiraglutidePrulifloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Prulifloxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Prulifloxacin.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Loratadine.Approved, Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Prulifloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Prulifloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Prulifloxacin.Investigational
MecaserminPrulifloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Prulifloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Prulifloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Prulifloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Mepyramine.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Prulifloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Prulifloxacin.Approved
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Prulifloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Prulifloxacin.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Prulifloxacin.Approved, Investigational
MifepristonePrulifloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPrulifloxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Prulifloxacin.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Prulifloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Prulifloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Prulifloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved
NateglinidePrulifloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Prulifloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Prulifloxacin.Approved, Investigational
NifenazoneNifenazone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Prulifloxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Prulifloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Prulifloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Prulifloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Prulifloxacin.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Ondansetron.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Prulifloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Prulifloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Prulifloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Prulifloxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prulifloxacin.Approved, Vet Approved
PalmidrolPalmidrol may increase the neuroexcitatory activities of Prulifloxacin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Prulifloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Prulifloxacin.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Prulifloxacin.Approved, Investigational
ParthenolideParthenolide may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
PentamidinePrulifloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Prulifloxacin.Experimental
PhenindionePrulifloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Pheniramine.Approved
PhenprocoumonPrulifloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Prulifloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Prulifloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
PioglitazonePrulifloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Prulifloxacin.Experimental
PramlintidePrulifloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Prulifloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Prulifloxacin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Prulifloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Prulifloxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Prulifloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Prulifloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Prulifloxacin.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Prulifloxacin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Prulifloxacin.Experimental
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Prulifloxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Propafenone.Approved
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Prulifloxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Prulifloxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Quetiapine.Approved
QuinaprilQuinapril can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuininePrulifloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinidePrulifloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Prulifloxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Prulifloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Prulifloxacin.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Prulifloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Prulifloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Prulifloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Prulifloxacin.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Prulifloxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Prulifloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Prulifloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Prulifloxacin.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Prulifloxacin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Prulifloxacin.Investigational
Strontium ranelateThe serum concentration of Prulifloxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Prulifloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazinePrulifloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazolePrulifloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Prulifloxacin.Approved
SulfisoxazolePrulifloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
SunitinibPrulifloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Prulifloxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Prulifloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Prulifloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Prulifloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Prulifloxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Prulifloxacin.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Terodiline.Experimental
TheophyllineThe metabolism of Theophylline can be decreased when combined with Prulifloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Prulifloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
TioclomarolPrulifloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Prulifloxacin.Approved, Withdrawn
TolazamidePrulifloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamidePrulifloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Prulifloxacin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Prulifloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Prulifloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Prulifloxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Prulifloxacin.Approved
TromethamineTromethamine can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Prulifloxacin.Approved
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Prulifloxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Valproic Acid.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Prulifloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Prulifloxacin.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Prulifloxacin.Approved
WarfarinPrulifloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Prulifloxacin.Approved, Investigational, Withdrawn
Zinc acetateZinc acetate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc chlorideZinc chloride can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc oxideZinc oxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Prulifloxacin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
65947
PubChem Substance
347828227
ChemSpider
59351
ChEBI
32071
ChEMBL
CHEMBL422648
Wikipedia
Prulifloxacin
ATC Codes
J01MA17 — Prulifloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentChronic Bacterial Prostatitis1
2Unknown StatusTreatmentUrinary Tract Infections (UTIs)1
3CompletedTreatmentAcute Bacterial Gastroenteritis1
3CompletedTreatmentAcute Gastroenteritis in Adult Travelers1
3CompletedTreatmentAcute Lower Urinary Tract Infection1
3Unknown StatusTreatmentAcute Exacerbation of Chronic Bronchitis (AECB)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.593 mg/mLALOGPS
logP1.77ALOGPS
logP2.49ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)6.03ChemAxon
pKa (Strongest Basic)5.16ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.62 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity127.37 m3·mol-1ChemAxon
Polarizability44.94 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Aminoquinolines and derivatives / Haloquinolines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Alkylarylthioethers / Aralkylamines
show 18 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Dihydroquinolone / Haloquinoline / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aryl thioether
show 36 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da

Drug created on October 20, 2016 14:57 / Updated on August 15, 2018 13:58